FDA Approves Daklinza/Sovaldi to Treat Hep C Genotype 1

The regimen has been well-studied in combination with numerous HIV antiretrovirals (ARVs). According to BMS, there is no need to adjust the dose of ARVs when used in combination with Daklinza and Sovaldi. Instead, the Daklinza dose can be adjusted if necessary—a shift that is not possible with fixed-dose combination tablet treatments.
To read the updated drug label, click here.
Last Updated on May 11, 2020 by HepFree NYC
Tags: Hepatitis C HepCX News Pharmaceutical








